INTRODUCTION
Social phobia is characterized by marked and persistent fear of embarrassment or humiliation in situations involving performance or interaction with or scrutiny by others. Social phobia is a relatively common disorder causing impaired social and occupational adaptation. The lifetime prevalence of social phobia is 13.3% (ref 1 ). It is a chronic disorder which often begins in puberty and adolescence, has a continuous course and leads to serious consequences 2 . It has a low rate of natural remission, producing substantial decrease in the quality of life and a large number of social role impairments and disabilities. Social phobia occurs in males and females in the same frequency. There is no influence of intelligence, education, economic background or employment on its occurrence 3 . People with social phobia tend to be financially dependent, often need specialized care, have more suicidal thoughts and suicide attempts, show increased risk of secondary psychiatric comorbidity, especially alcohol abuse and addiction, depression, are rarely married and have major difficulties with work adaptation 4 . Population and clinical studies also show that these patients are seldom treated adequately [5] [6] [7] [8] . Over the past 15 years, behavioral, cognitive, and cognitive behavioral procedures (primarily exposure and cognitive reconstruction based treatments) have been found effective in the treatment of social phobia. Cognitive behavioral therapy (CBT) is typically a timelimited psychosocial intervention, administered either in individual or group settings, that has demonstrated clear efficacy for the treatment of SAD 9, 10 . Typical components of CBT include psychoeducation, somatic management techniques such as muscle relaxation, in vivo and imaginal exposure, video feedback, cognitive restructuring, and social skills training 9, 11 . CBT has demonstrated efficacy comparable to that of pharmacotherapy, with a slightly slower onset of therapeutic effect but greater persistence of benefit after treatment discontinuation [12] [13] [14] [15] [16] . Members in group CBT program have the opportunity to try out and practice basic social skills which they can use later in their natural environment 17 . From the long term point of view it can be more effective than pharmacotherapy (SSRI use) only. In comparison with the general population, however, one study showed that while two thirds of patients significantly improve only about half reached normal levels of anxiety in social situations after treatment 3 . Although combined pharmacotherapy and CBT may be presumed to be more effective than either intervention administered individually, evidence from one large RCT with fluoxetine and CBT did not demonstrate a significant advantage for the combined intervention over each effective monotherapy 18 . In a study from our department Prasko et al. 17 compared the effectiveness of a 6 month and 2 year follow up of three outpatient treatment programs (moclobemide with clinical management, cognitive -behavioral therapy with placebo, and the combination of moclobemide with cognitive behavioral therapy) in patients with social phobia. All three therapeutic approaches proved highly effective. Moclobemide alone was the most immediate in reducing general anxiety and social anxiety in the first two months of treatment but its influence on behavior was less expressed. The combination of pharmacotherapy and CBT was the most effective in the 6-month assessments in all measures. CBT with placebo was most effective in reducing avoidant behavior but the reduction in anxiety itself manifest later than for moclobemide. In a two-year follow up, the best on all rating scales were groups initially treated with CBT with placebo or CBT with moclobemid.
Personality disorders are relatively frequent in the general population with a prevalence ranging from 10% to 13% (ref 19 ). Among the outpatient psychiatric population, 30-50% suffers from personality disorders 20 and about 15% of inpatients come to health care facilities because of problems related primarily to their personality disorders. Up to half of the remaining inpatients suffers from comorbid personality disorder 21 . Social phobia can be associated with any personality disorder, particularly with an avoidant one. People with social phobia, however, often suffer from other personality disorders, such as borderline, narcissistic, dependent and paranoid disorders 17 . A diagnosis of personality disorder often evokes images of troublesomeness, difficult work with little hope for success and this correspondingly affects the therapist's conscious or unconscious attitudes from the very beginning of his relationship with the patient. These attitudes are often negative, moralising and, according to Tyrer and Davidson 22 , sometimes rigid or even "delusional". Personality disorders rarely occur separately and are often related to other health problems, such as depressive states, anxiety disorders, eating disorders, alcohol and drug abuse, promiscuity, injury, infectious diseases etc. Most clinicians believe that the occurrence of these problems in tandem with a personality disorder often leads to longer treatment, worsens the prognosis, and thus increases treatment costs. However, the latest overview of empirical psychotherapeutic studies of personality disorders shows that, despite the myth of untreatability, treatment is relatively effective 23 . The authors carried out a meta-analysis of 22 studies showing that significant positive changes during active treatment are 2-4 times higher than in control groups without any active treatment. In four studies with treatment outcome criterion of full remission, 52% of patients met this criterion after 1.3 years of treatment. Although the improvement is not as fast and substantial as for anxiety disorders or depression, there is still a significant reduction in the patients' suffering and improvement in their adaptation in life. This metaanalysis, however, is not clinically relevant to the answer the question: Does comorbid disorder influence the treatment efficacy for any particular disorder? In our study 24 we found that there is smaller decline in specific panic and agoraphobic symptoms during treatment in patients with comorbid personality disorder than in patients without personality disorder. Nonetheless, there was also a significant reduction in anxiety and avoidance symptoms in patients with panic disorder/agoraphobia comorbid with personality disorders. A high percentage of these patients achieved significant overall improvement. However there is a dearth of information on co-morbidity of personality disorders in the treatment of social phobia. According to clinical perception, social phobia with comorbid personality disorder is more difficult to treat than social phobia without comorbid personality disorders 25 . Approximately half of all patients admitted for social phobia to the day-care clinic of Prague Psychiatric Centre also suffer from comorbid personality disorder. Prevailing personality disorders include avoidant, borderline, narcissistic and dependent. The therapeutic programme for social phobia patients with or without personality disorders is practically the same; it lasts six weeks, unless a patient decides to quit the therapy earlier. The aim of our study was to compare the efficacy of treatment in patients with social phobia suffering from a comorbid personality disorder with the treatment of patients with social phobia with no comorbid personality disorder.
METHOD
The sample includes outpatients coming for intensive group psychotherapeutic treatment to Prague Psychiatric Center for a generalized form of social phobia. The diagnosis was confirmed by two experienced psychiatrists.
Patients
To date, 35 patients who met the following admission criteria have been included into the study (18 The inclusion and exclusion criteria of the study were confirmed by two independent experts. The study was approved by a joint ethical committee of the Prague Psychiatric Centre and the Psychiatric Hospital in Bohnice.
Assessment
After study enrolment, patients were assessed during the first two days of attendance at the day-care clinic before the beginning of treatment. The assessment focused on psychopathology and was carried out using psychiatric rating scales in the second, fourth and sixth week by two trained psychiatrists or with self-rating scales (Table 1) .
(a) Objective rating scales -to assess the degree of psychopathology, we used following psychiatric rating scales:
28 ) -global assessment of the degree of psychopathology. The source of the data is an as complete as possible collection of information about the patient's behaviour.
• LSAS (Liebowitz Social Anxiety Scale) (ref. 29 ) -the most commonly used scale to measure symptoms of social phobia. The patient scores in the 24 items representing typical feared social situation in two subscales (social anxiety and avoidant behavior) from 0 (no anxiety or avoidant behavior) to 3 (maximum distress or full avoidant behavior).
Self assessment rating scales:
• BAI -(Beck Anxiety Inventory) (ref. 30 ) -self-rating scale with 21 anxiety indicators;.
• BDI -(Beck Depression Inventory)(ref. 31 ) -self-rating scale with 21 depression indicators.
Therapeutic approaches
All patients were treated in group cognitive-behavioral program for patients with various anxiety disorders. The CBT group program includes 18 groups of CBT (vicious circle of anxiety, cognitive restructuring, communication training, role playing, exposure therapy, relaxation, cognitive schemas accommodation, and problem solving) and 12 biographical groups which address the mapping and elaborating of cognitive schemas. Each session lasted 1.5 hour and homework is an integral part of the program. The brief CBT program is focused on the treatment of anxiety disorders and is not targeted for the treatment of personality disorders. The concrete steps of the program are described in detail in the manual 32 . Pharmacotherapy with SSRI antidepressants was administered if patients wished. If a patient came to the treatment without drugs or disagreed with the using of medication, he/she was treated with CBT only (13 patients). Medicated patients were taking SSRI in the normal range and during the CBT program this remained unchanged. A few patients were receiving low doses of second generation antipsychotics and we did not change it. Eight patients were also using small doses of anxiolytics (alprazolam, average dose 1.15 mg per day, range 0.75 -1.5). We gradually decreased doses in all patients to be free of anxiolytics at the end of the treatment.
Statistical methods
Descriptive statistics were applied to all demographic variables. Only patients, who completed the 6-month treatment, were included in the analysis. The data are presented as means and SD. Patient demographic and baseline clinical characteristics were compared between treatment groups and analyzed using the two-sample t-test or the Mann-Whitney U test and chi-square test or Fisher's exact test for continuous and categorical variables, respectively. The data for the LSAS, CGI and BAI passed the normality testing (Kolmgorov-Smirnov). Analysis of variance (ANOVA) was used to evaluate the change in psychometric measures during the study. The interaction between group and time was evaluated by a two-way ANOVA. The chi 2 -test was used in analyzing the change in the CGI score. For all statistical tests a 5% significance level was chosen. Statistical computing was performed with Statsoft Statistica version 7.0 software).
RESULTS
Thirty five patients were eventually included into the study (16 men and 19 women). Seventeen patients fulfilled ICD-10 research criteria for comorbid personality disorder (for patients characteristics see Table 2 ). There were no statistically significant differences among the patients suffering from social phobia with comorbid per- Table 2 ), or in mean scores of rating scales CGI, LSAS and BAI (unpaired t-test: ns; see Table  3 ) at the beginning. Nevertheless the group with personality disorders had a statistically significant lower level of education than the group without personality disorders (chi 2 : p <0.005), and a statistically significant higher frequency of comorbid current disorders (chi 2 : p <0.05) (see Table 2 ). There was also a significant difference between groups in the subjective evaluation of depressive symptoms -the group with comorbid personality disorders subjectively experienced higher rates of depression (as assessed by BDI, unpaired t-test: p<0.005, see Table 3 ).
The borderline (29%) and avoidant (29%) personality disorder were the most common personality disorder comorbid with social phobia in our study. Comorbidity of other psychiatric disorders in both groups was relatively large: thirteen patients (i.e. 76%) of group with social phobia and personality disorders and eight patients (i.e. 44%) of group with social phobia without personality disorder suffered from other current psychiatric disorder (Table 2) . There was higher percentage of other comorbid psychiatric disorders in the group with personality disorder than in the group without personality disorders (difference between groups was statistically significant: chi 2 : p <0.05). Our hypothesis, that social phobia patients with personality disorder suffer significantly more often from current comorbidity disorders than the social phobias patients without personality disorder, was confirmed.
Treatment
Patients were treated with group CBT and pharmacotherapy or with group CBT only (13 patients). The CBT programme was standardized. Twelve patients used medication (i.e. 71%) of the group with personality disorders and ten patients (i.e. 56%) of the group without personality disorders. There was no significant difference in medication use between the groups.
CGI-severity
In the beginning, there were no significant differences in the severity scores of clinical global impression scale (5.06 + 0.56 for the patients with personality disorders versus 4.72 + 0.67 for the patients without personality disorder, unpaired t-test: n.s.). The severity scores decreased significantly in both groups during treatment (week 6: 3.47 + 0.87, one-way ANOVA for repeated measures: F= 36.09; p<0.0001 for the group with personality disorders, versus 2.33 + 0.59, one-way ANOVA for repeated measures: F= 91.63; p<0.0001 for the group without personality disorders). There was statistically significant higher change in mean score in the group of patients without personality disorders (week 0-6: change in mean CGI score of the patients with personality disorders was 1.59 ± 0.19, change in mean CGI score of the patient without personality disorder was 2.39 ± 0.16, unpaired t-test: t=3.171; p<0.005). Nevertheless there was no statistically significant interaction between groups and time in the two-way ANOVA for repeated measures (F= 2.206; p= 0.09) (Fig. 1) . Clinical remission was assumed when a patient achieved CGI-severity rating 1 (without symptoms) or 2 (minimal symptoms). There were only 2/ 17 patients of the group with personality disorders achieved these figures after 6 weeks of therapy (11%) while 13/ 18 patients from the group without personality disorder (72%). This difference was statistically significant (Fisher exact test: p <0.0005).
BAI
There were surprising results for the BAI scores. The baseline scores were comparable (20.24 + 10.41 in the group with personality disorders versus 18.94 + 8.38 in the group without personality disorders; unpaired t-test: ns). In the first two weeks there was a slight non significant increase in general anxiety symptoms in both groups (24.41 + 8.80 in the group with personality disorders and 22.56 + 10.63 in the group without personality disorders; unpaired t-test: ns). Mean scores were reduced in both groups during the course of treatment (at week 6: 18.76 + 14.33 + 2.431 vs. 1.597, unpaired t-test: ns.) (Fig. 2) . The initial increase was probably related to the start of exposure therapy. The patients typically avoided social situations before the therapy and after the start of the treatment they were gradually exposed to social situations. The course of symptom reduction was very similar in both groups (one-way ANOVA for repeated measures: F=3.222; p<0.05) in the group with personality disorders and F=5.772; p<0.005 in group without personality disorders (Table 3) but there was no statistically significant interaction between groups and time in two-way ANOVA Is there any influence of personality disorder on the short term intensive group cognitive behavioral therapy of social phobia? 
Mean score
Social phobia with personality disorder Social phobia without personality disorder Two -way ANOVA: ns *** * *** **** *p<0.05; *** p<0.005 **** p<0.001 for repeated measures (F= 0.325; p=0.807). The pattern of symptom increase and decrease was very similar for both groups. No significant difference was found in either of the study visit. Subjective evaluation of a wide range of anxiety symptoms in the BDI rating scale confirmed these data. Social phobia patients -with or without personality disorder -improved rapidly during short-term treatment programme. If we ignore the specific symptoms for which they were admitted and treated, the changes are similar.
BDI
The Beck Depression Inventory is designed for evaluating subjective depression symptoms. There was a statistically significant difference between groups in baseline depression scores (23.65 + 8.45 for patients with personality disorders versus 14.72 + 6.45 in the second group, unpaired t-test: p <0.005). The mean score for the group with personality disorders was consonant with mild depression. There were similar changes in depression ratings during the treatment for both groups (mean score at week 6 in the group with personality disorder was 18.47 + 9.17, one-way ANOVA for repeated measures F=4.31; p <0.005; and in the group without personality disorder was 8.5 + 6.00; one -way ANOVA for repeated measures: F=5.289; p <0.001). There was no statistically significant interaction between groups and time in the two-way ANOVA for repeated measures (F=0.080; p=0.971) (Fig. 3) . Anxiety subscale of LSAS (LSAS-AX): There were no statistically significant differences at the beginning between the groups (mean score 41.12 + 10.78 for patients with personality disorders versus 37.61 + 12.87 in patients without personality disorder, unpaired t-test: ns). During the treatment, both groups significantly improved (mean score 32.41 + 11.55, one-way ANOVA for repeated measures: p <0.0001 in patients with personality disorders versus 21.78 + 10.28 in patients without personality disorders, one-way ANOVA for repeated measures: p <0.0001 ). There was no statistically significant interaction between groups and time in the two-way ANOVA for repeated measures (F= 0.757; p=0.520) (Fig. 4) .
Avoidant behavior subscale (LSAS-AB): There was no statistically significant difference between groups at the beginning (mean score 34.53 + 14.72 for patients with personality disorders versus 35.39 + 13.51 for patients without personality disorders, unpaired t-test: ns). The mean scores of both groups decreased during treatment (the group with a personality disorder to a mean score 25.65 + 15.94, one-way ANOVA for repeated measures: p <0.005, while the group without personality disorders to the mean score 18.61 + 9.80, one-way ANOVA for repeated measures: p <0.001). There was no statistically significant interaction between groups and time in twoway ANOVA for repeated measures (F= 0.088; p= 0.768) (Fig. 5) . (Fig. 6 ).
DISCUSSION
The results show that patients from both groups improved significantly on all ratings scales. A combination of CBT and pharmacotherapy proved to be the most effective treatment for patients suffering from social phobia with or without comorbid personality disorder. Treatment efficacy in patients with social phobia without personality disorder was shown to be slightly better than the group with social phobia comorbid with personality disorder but according the quantitative rating scales (objective and subjective) the differences between groups did not reach statistical significance. Nevertheless more patients without personality disorder reached the clinical remission than patient with personality disorder. Thus it is possible that the intensive 6-week group CBT program is long enough for patients with social phobia without a personality disorder, while it is too short for patients with social phobia with personality disorder. Another hypothesis -that in addition to social phobia, personality disorder patients would more frequently suffer from other comorbid disorders -was confirmed. The presence of comorbid disorders has been associated with longer duration of social phobia as well as a more severe impairment before and after cognitive-behavioral therapy treatment 33 . There are surprising results for the Beck Anxiety Inventory. The general anxiety symptoms increased in the second week of the treatment for both groups. We believe that this initial rise in anxiety symptoms is a consequence of the start of the exposure therapy. The mean scores of BAI decreased in subsequent weeks in both groups.
The anxiety level of both groups of patients during therapy significantly improved on the Liebowitz Social Anxiety Scale, which is the most important instrument for the measurement of social phobia symptom severity. The outcome was not significantly better in patients without personality disorders than in patients with personality disorders. There was improvement in the avoidant behavior subscale in both groups. The change was also not significantly higher in patients without personality disorders. Surprisingly we did not find any prominent disproportion between the objective and subjective measures of rating scales between group of personality disorder patients and group of patients without personality disorders.
There were statistically significant differences between the groups in depressive symptoms measured with the Beck depression inventory at the start of the treatment. It seems that the patients with social phobia with a personality disorder entered into the study with more depressive symptoms than patients without personality disorders. This fact can affect the whole course of treatment, because a higher level of subjective depressive symptoms is associated with worse collaboration with exposure therapy. However, there was only mild severity of depression among the patients with social phobia and personality disorders on average. There are several another limitations of our study. Although no significant differences between treatment groups were detected, the patients without personality disorders had a somewhat greater reduction in LSAS and CGI. Our negative findings may be related to type II error. There is also a small group size. Therefore the comparisons of these two groups have limitations.
Perry and Bond 23 claim that, despite earlier assumptions about untreatability; treatment of personality disorders is relatively effective. In all studies they reviewed, the improvement in personality disorder patients was not as pronounced as in patients without personality disorders but it exists. Our group described similar results in an earlier study with panic disorder and personality disorders 24 .
CONCLUSION
Patients suffering from social phobia and comorbid personality disorder showed a decrease in specific social phobia symptomatology during the intensive short 6 week treatment even though the results were less pronounced than those for patients suffering from social phobia without personality disorder. 
